on October 12, 2006
Published online before print October 12, 2006, doi: 10.1161/01.ATV.0000249630.02085.12
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 6, 2006
Accepted on September 28, 2006
Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes
Chiara Cuccurullo ;
From Atherosclerosis, Hypertension and Dyslipidemia Unit (C.C., A.I., M.L.F., D.C., A.D., R.M., S.U., F.S., F.C., F.Cuccurullo, A.M., F. Cipollone), "G.d’Annunzio" University of Chieti-Pescara, and the Center for Aging Sciences,"G. d’Annunzio" University Foundation, Chieti-Pescara, Italy; Department of Experimental Medicine and Pathology (R.B.), University of Rome Tor Vergata, School of Medicine, Rome, Italy; Columbia University (A.M.S.), New York, NY.
* To whom correspondence should be addressed. E-mail: fcipollone{at}unich.it.
Objective--Receptor for advanced glycation end products (AGEs) (RAGE) plays a central role in the process of plaque rupture in diabetic patients. Recently, it has been reported that RAGE may be downregulated by improving glycemic control. In contrast, despite being well known that RAGE may be induced in human vessels in a glucose-independent fashion, also by myeloperoxidase (MPO)-dependent AGE generation, no data exist regarding the possibility of a pharmacological modulation of glucose-independent RAGE generation. Thus, the aim of this study was to characterize the effect of simvastatin on the expression of RAGE and RAGE-dependent plaque-destabilizing genes in human atherosclerotic plaques.
Methods and Results--Seventy type 2 diabetic patients with asymptomatic carotid artery stenosis (>70%) were randomized to American Heart Association (AHA) step 1 diet plus simvastatin (40 mg/d) or AHA step 1 diet alone for 4 months before endarterectomy. Plaque expression of MPO, AGEs, RAGE, NF-
B, COX-2, mPGES-1, matrix metalloproteinase (MMP)-2 and MMP-9, lipid and oxLDL content, procollagen 1, and interstitial collagen was analyzed by immunohistochemistry and Western blot; zymography was used to detect MMP activity. Plaques from the simvastatin group had less (P<0.0001) immunoreactivity for MPO, AGEs, RAGE, p65, COX-2, mPGES-1, MMP-2, and MMP-9, lipids and oxLDL; reduced (P<0.0001) gelatinolytic activity; increased (P<0.0001) procollagen 1 and collagen content; and fewer (P<0.0001) macrophages, T-lymphocytes, and HLA-DR+ cells. Of interest, RAGE inhibition by simvastatin, observed not only in plaque sections but also in plaque-derived macrophages, was reverted by addition of AGEs in vitro.
Conclusions--This study supports the hypothesis that simvastatin inhibits plaque RAGE expression by decreasing MPO-dependent AGE generation. This effect in turn might contribute to plaque stabilization by inhibiting the biosynthesis of PGE2-dependent MMPs, responsible for plaque rupture.
Key words: diabetes mellitus • metalloproteinases • myeloperoxidase • RAGE • statins
This article has been cited by other articles:
 |
|
 |
|
  H. K. Takahashi, K. Liu, H. Wake, S. Mori, J. Zhang, R. Liu, T. Yoshino, and M. Nishibori Prostaglandin E2 Inhibits Advanced Glycation End Product-Induced Adhesion Molecule Expression, Cytokine Production, and Lymphocyte Proliferation in Human Peripheral Blood Mononuclear Cells J. Pharmacol. Exp. Ther., November 1, 2009; 331(2): 656 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wake, H. K. Takahashi, S. Mori, K. Liu, T. Yoshino, and M. Nishibori Histamine Inhibits Advanced Glycation End Products-Induced Adhesion Molecule Expression on Human Monocytes J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 826 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Takahashi, S. Mori, H. Wake, K. Liu, T. Yoshino, K. Ohashi, N. Tanaka, K. Shikata, H. Makino, and M. Nishibori Advanced Glycation End Products Subspecies-Selectively Induce Adhesion Molecule Expression and Cytokine Production in Human Peripheral Blood Mononuclear Cells J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Doupis, T. E. Lyons, S. Wu, C. Gnardellis, T. Dinh, and A. Veves Microvascular Reactivity and Inflammatory Cytokines in Painful and Painless Peripheral Diabetic Neuropathy J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2157 - 2163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B Lindsey, F. Cipollone, S. M Abdullah, and D. K Mcguire Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications Diabetes and Vascular Disease Research, January 1, 2009; 6(1): 7 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 Z Sternberg, B Weinstock-Guttman, D Hojnacki, P Zamboni, R Zivadinov, K Chadha, A Lieberman, L Kazim, A Drake, P Rocco, et al. Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity Multiple Sclerosis, July 1, 2008; 14(6): 759 - 763. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Ye, J. D. Martinez, R. J. Perez-Polo, Y. Lin, B. F. Uretsky, and Y. Birnbaum The role of eNOS, iNOS, and NF-{kappa}B in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H343 - H351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Marsche, B. Weigle, W. Sattler, and E. Malle Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein FASEB J, October 1, 2007; 21(12): 3075 - 3082. [Abstract] [Full Text] [PDF]
|
|